All Immunology articles
-
NewsVaccine adjuvant AS01 shown to induce trained immunity in monocytes
A preclinical study published in Myeloid Cells reports that AS01, a vaccine adjuvant system, can induce trained immunity in human monocytes and reduce tumour growth in selected mouse cancer models.
-
NewsWhat SIRPα reveals about how breast cancer takes hold in the brain
Scientists at Wake Forest University School of Medicine have uncovered a previously unrecognised cancer-intrinsic role for SIRPα in triple-negative breast cancer, linking the cell-surface protein to mitochondrial fission, tumour-cell migration and suppression of the brain’s immune defences.
-
NewsBCG and immunotherapy combination cuts tuberculosis relapse risk
Combining the BCG vaccine with a B-cell-targeting immunotherapy significantly reduced tuberculosis relapse rates in preclinical models.
-
NewsSalk researchers uncover how interferons switch from anti- to pro-cancer
Researchers at the Salk Institute have identified a cellular pathway through which prolonged interferon exposure triggers mitochondrial dysfunction, PGE2 production and suppression of anti-tumour immunity – offering a potential strategy for overcoming immunotherapy resistance.
-
NewsExperimental RNA drug reverses scleroderma signs in preclinical study
An experimental synthetic non-coding RNA drug has reversed signs of systemic sclerosis in patient-derived immune cells and mouse models, with researchers now preparing an IND application to the FDA.
-
NewsPeptide vaccine targeting PCSK9 reduces cholesterol and atherosclerotic plaque in mice
A structure-guided peptide vaccine targeting PCSK9 has reduced LDL cholesterol and atherosclerotic plaque burden in mouse models, offering a potential longer-lasting alternative to existing PCSK9-targeting biologics, though primate results remain inconclusive.
-
NewsRegnase-1 deletion boosts CAR T-cell efficacy against paediatric osteosarcoma
St Jude researchers have demonstrated that deleting the Regnase-1 gene from CAR T cells significantly improves tumour control and prevents metastasis in preclinical models of relapsed osteosarcoma, paving the way for an early-phase clinical trial.
-
NewsHER3-DXd and olaparib combination boosts lung cancer treatment responses
A new preclinical study finds that combining the antibody-drug conjugate HER3-DXd with PARP inhibitor olaparib significantly improves treatment responses in NSCLC models, including those harbouring EGFR and KRAS mutations, by overwhelming DNA repair capacity and activating innate immune signalling.
-
NewsIL-17 identified as potential immunotherapy biomarker in ovarian cancer
A new study has identified IL-17 as a potential biomarker for immunotherapy response in a small subset of clear cell ovarian cancer cases, offering a possible route to personalised treatment for a disease historically resistant to immune-based therapies.
-
NewsExhausted T cells escape tumours to drive lasting cancer immunity
A preclinical study has identified a subset of exhausted, LAG3-expressing T cells capable of migrating out of tumours to establish long-term immune memory, with potential implications for LAG3-targeting cancer immunotherapies.
-
NewsScientists identify a new vaccine design strategy for stronger HIV immunity
Two preclinical studies published in Science Translational Medicine suggest that the binding strength and structural repetitiveness of vaccine nanoparticles could be a critical design parameter in the long-running effort to generate broadly neutralising antibodies against HIV.
-
NewsTissue chips target immunotherapy toxicity prediction without animal models
Researchers at the University of Rochester have developed human cell-based tissue chips designed to predict serious immunotherapy toxicities, including cytokine release syndrome, and have secured entry into the FDA’s ISTAND pilot programme.
-
NewsWhat Oblenio’s Phase I trial means for autoimmune drug discovery
Oblenio Bio has dosed the first patients in a Phase 1a trial of LBL-051, a tri-specific T cell engager designed to simultaneously target CD19, BCMA and CD3 and eliminate both B cells and plasma cells in a bid to achieve durable immune reset in refractory autoimmune diseases.
-
NewsHow dendritic cells organise tumour immunity – and why drug developers should take notice
A new study published in Science identifies a specialised dendritic cell subset as the cellular architects behind tertiary lymphoid structures, offering a potential new target for boosting anti-tumour immunity and converting immunologically cold tumours into treatment-responsive ones.
-
WebinarMeeting ethical & regulatory requirements when using human biological specimens
Whether you source, purchase or work with human biospecimens, understanding today’s ethical and regulatory expectations is essential. Join this webinar to explore informed consent, privacy and the principles that support responsible research.
-
NewsPCSK9 peptide vaccine lowers LDL cholesterol in preclinical studies
A structure-guided peptide vaccine targeting PCSK9 has demonstrated durable antibody responses and reduced LDL cholesterol levels in mouse models of hypercholesterolaemia, offering a potential long-lasting alternative to current lipid-lowering therapies.
-
NewsVitronectin protein identified as key driver of lung scarring
Researchers from UTS and Monash University have identified vitronectin as a key protein driving abnormal lung scarring in idiopathic pulmonary fibrosis, opening a potential new avenue for therapeutic intervention in a disease with very few treatment options.
-
NewsExperimental HIV vaccine generates broadly neutralising antibodies in primates
A collaborative research team from LJI, Scripps Research and IAVI has developed an experimental HIV vaccine that successfully generated broadly neutralising antibodies in rhesus macaques, marking a pivotal advance in the 14-year effort to design an effective HIV vaccine.
-
NewsPeptide vaccine targeting PCSK9 proves effective in cardiovascular disease models
A peptide vaccine targeting PCSK9 has demonstrated sustained antibody responses and reductions in LDL cholesterol and atherosclerotic plaque formation in animal models, offering a potential long-term alternative to current lipid-lowering therapies.
-
NewsEpilepsy drug sodium valproate could improve vaccine immune responses
A commonly prescribed epilepsy drug has shown striking potential as a vaccine booster in a controlled human trial, more than doubling antibody levels and increasing T cell responses tenfold at a fraction of its standard therapeutic dose.